Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy

Kowichi Jimbow, Tomoaki Takada, Toshiharu Yamashita, Makito Sato, Akiko Sato, Ichiro Ono, Yasuaki Tamura, Noriyuki Sato, Atsushi Miyamoto, Akira Ito, Hiroyuki Honda, Kazumasa Wakamatsu, Shosuke Ito

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF). This study tested if a chemo-thermo- immunotherapy (CTI therapy) strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite nanoparticles (NPrCAP/M). We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth. The therapeutic protocol against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant. The heat-generated therapeutic effect was more significant at a temperature of 43 °C than either 41 °C or 46 °C. NPrCAP/M with AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most significant growth inhibition of the re-challenge tumor and increased the life span of the mice. HSP70 production was greatest at 43 °C compared to that with 41 °C or 46 °C. CD 8+T cells were infiltrated at the site of the re-challenge melanoma transplant.

Original languageEnglish
Article number457936
JournalJournal of Biomedicine and Biotechnology
Volume2009
DOIs
Publication statusPublished - Dec 9 2009

Fingerprint

Magnetite Nanoparticles
Transplants
Experimental Melanomas
Immunotherapy
Melanoma
Magnetic Fields
Magnetic fields
Substrates
Growth
Tumors
Ferrosoferric Oxide
Neoplasms
Temperature
T-cells
Therapeutic Uses
Heat-Shock Proteins
Free Radicals
Hot Temperature
Cells
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Health, Toxicology and Mutagenesis

Cite this

Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy. / Jimbow, Kowichi; Takada, Tomoaki; Yamashita, Toshiharu; Sato, Makito; Sato, Akiko; Ono, Ichiro; Tamura, Yasuaki; Sato, Noriyuki; Miyamoto, Atsushi; Ito, Akira; Honda, Hiroyuki; Wakamatsu, Kazumasa; Ito, Shosuke.

In: Journal of Biomedicine and Biotechnology, Vol. 2009, 457936, 09.12.2009.

Research output: Contribution to journalArticle

Jimbow, Kowichi ; Takada, Tomoaki ; Yamashita, Toshiharu ; Sato, Makito ; Sato, Akiko ; Ono, Ichiro ; Tamura, Yasuaki ; Sato, Noriyuki ; Miyamoto, Atsushi ; Ito, Akira ; Honda, Hiroyuki ; Wakamatsu, Kazumasa ; Ito, Shosuke. / Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy. In: Journal of Biomedicine and Biotechnology. 2009 ; Vol. 2009.
@article{243369cf467c46ba8bc6cda5e6275f0e,
title = "Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy",
abstract = "Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF). This study tested if a chemo-thermo- immunotherapy (CTI therapy) strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite nanoparticles (NPrCAP/M). We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth. The therapeutic protocol against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant. The heat-generated therapeutic effect was more significant at a temperature of 43 °C than either 41 °C or 46 °C. NPrCAP/M with AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most significant growth inhibition of the re-challenge tumor and increased the life span of the mice. HSP70 production was greatest at 43 °C compared to that with 41 °C or 46 °C. CD 8+T cells were infiltrated at the site of the re-challenge melanoma transplant.",
author = "Kowichi Jimbow and Tomoaki Takada and Toshiharu Yamashita and Makito Sato and Akiko Sato and Ichiro Ono and Yasuaki Tamura and Noriyuki Sato and Atsushi Miyamoto and Akira Ito and Hiroyuki Honda and Kazumasa Wakamatsu and Shosuke Ito",
year = "2009",
month = "12",
day = "9",
doi = "10.1155/2009/457936",
language = "English",
volume = "2009",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy

AU - Jimbow, Kowichi

AU - Takada, Tomoaki

AU - Yamashita, Toshiharu

AU - Sato, Makito

AU - Sato, Akiko

AU - Ono, Ichiro

AU - Tamura, Yasuaki

AU - Sato, Noriyuki

AU - Miyamoto, Atsushi

AU - Ito, Akira

AU - Honda, Hiroyuki

AU - Wakamatsu, Kazumasa

AU - Ito, Shosuke

PY - 2009/12/9

Y1 - 2009/12/9

N2 - Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF). This study tested if a chemo-thermo- immunotherapy (CTI therapy) strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite nanoparticles (NPrCAP/M). We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth. The therapeutic protocol against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant. The heat-generated therapeutic effect was more significant at a temperature of 43 °C than either 41 °C or 46 °C. NPrCAP/M with AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most significant growth inhibition of the re-challenge tumor and increased the life span of the mice. HSP70 production was greatest at 43 °C compared to that with 41 °C or 46 °C. CD 8+T cells were infiltrated at the site of the re-challenge melanoma transplant.

AB - Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF). This study tested if a chemo-thermo- immunotherapy (CTI therapy) strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite nanoparticles (NPrCAP/M). We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth. The therapeutic protocol against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant. The heat-generated therapeutic effect was more significant at a temperature of 43 °C than either 41 °C or 46 °C. NPrCAP/M with AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most significant growth inhibition of the re-challenge tumor and increased the life span of the mice. HSP70 production was greatest at 43 °C compared to that with 41 °C or 46 °C. CD 8+T cells were infiltrated at the site of the re-challenge melanoma transplant.

UR - http://www.scopus.com/inward/record.url?scp=71149086160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71149086160&partnerID=8YFLogxK

U2 - 10.1155/2009/457936

DO - 10.1155/2009/457936

M3 - Article

C2 - 19830247

AN - SCOPUS:71149086160

VL - 2009

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 457936

ER -